Table 4.
Cox-regression model about predictors of acute hospitalization in PD patients after 1 year of follow-up (N = 605)
| HR (95% CI) | p | |
| Age | 1.002 (0.951–1.056) | 0.937 |
| Gender | 0.627 (0.267–1.469) | 0.282 |
| Disease duration | 0.838 (0.726 –0.968) | 0.016 |
| LEDD | 1.000 (0.999–1.001) | 0.614 |
| Total number of non-anti parkinsonian drugs | 0.839 (0.675–1.042) | 0.111 |
| UPDRS-III-OFF | 1.032 (0.991–1.074) | 0.128 |
| UPDRS-IV | 1.071 (0.909–1.260) | 0.413 |
| NMSS | 0.999 (0.989–1.009) | 0.823 |
| BDI-II | 1.016 (0.955–1.081) | 0.613 |
| PD-CRS | 0.986 (0.958–1.015) | 0.339 |
| NPI | 1.021(0.972–1.072) | 0.406 |
| Falls | 2.998 (1.080 –8.322) | 0.035 |
| Dysphagia | 1.593 (0.645–3.932) | 0.313 |
| ADLS | 1.004 (0.962–1.048) | 0.865 |
Hazard ratio; LEED, Levodopa equivalent daily dose; NMSS, Non-Motor Symptoms Scale; NPI, Neuropsychiatric Inventory; PD-CRS, Parkinson’s Disease Cognitive Rating Scale; UPDRS, Unified Parkinson’s Disease Rating Scale. The omnibus test indicated an overall significant model χ2 = 34,149 (p = 0.001).